Orphan Drugs and Rare Diseases UK 2017
 

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.

Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and re-purposing. 

Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.


Featured Speakers:

Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals

Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital

Oliver Timmis, CEO, AKU Society

Stuart Hughes, Director, Head of Pharmacology, Vertex

Nadia Assenova, Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH

Christine Lavery, Group Chief Executive, MPS Society

Hsin Loke, Director, Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline

Olaf Ritzeler, External Innovation Lead, Sanofi

Stephen Marcus, CEO, Cantex Pharmaceuticals

Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences


Exclusive highlights in 2017:

Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes

Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children

Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement, covering improvement strategies, patient-led trials, and much more

Gather further insight on drug approval and reimbursement with MAA, and how techniques for drug re-purposing in the rare disease area can help treatment


Related Events

Comments